91影库

Genetic diseases pass from parents to children — often in surprising ways. The unpredictability of these transfers means that sometimes a disease skips whole generations, while other times it may affect only one sibling. Pairs of affected and unaffected siblings provide a unique opportunity for scientists to study the molecular mechanisms of genetic disease.

Unraveling the connection between the genetic mutation a person carries and the symptoms they have has been a decades-long focus of Yi-Wen Chen’s laboratory, part of the Center for Genetic Medicine Research at Children’s National Hospital in Washington, D.C. Chen’s expertise is in genetic muscle disorders, which occur in adults in the United States.

Muscle weakness can sometimes start early – even in the womb. Other times, as is the case with the second-most common muscle disorder, adult-onset facioscapulohumeral muscular dystrophy, or FSHD, symptoms begin much later, in adolescence or early adulthood. Why is this, and does it hint at a way to design treatment?

To answer these questions, Chen’s laboratory teamed up with proteomics expert Jatin Burniston of the Research Institute for Sport and Exercise Sciences at Liverpool John Moores University. They studied affected and unaffected sibling pairs using proteomics experiments designed to reveal the underlying mechanisms of FSHD.

The researchers took cell cultures from each sibling and incubated them with deuterium, or “heavy water.” Then, they tracked the lifespan of each protein in the cell with mass spectrometry. The results, described in a  in Molecular & Cellular Proteomics, implicate slower turnover of mitochondrial proteins, but more abundant mitochondrial proteins in the sibling with FSHD. Slower turnover means old proteins — which should be recycled — pile up in the mitochondria, triggering stress responses and interrupting normal cell function. The finding is a clever combination of atomic-level detail and good biological controls.

Yusuke Nishimura, a postdoctoral research associate in Burniston’s lab was a co-first author on the paper.

“Mitochondrial dysfunction and mitochondrial stress in FSDH had been identified in previous studies,” Nishimura said. However, that information alone wasn’t enough to begin designing a treatment. Because FSHD varies widely between individuals, “studying (the) underlying biological mechanisms is challenging,” he said.

Differences in protein turnover observed when comparing FSDH patients with healthy individuals may not be caused by the disease, but simply be normal variances between unrelated people. That’s where the sibling pair comes in — by simultaneously analyzing a sibling with FSHD and a sibling without the disease, Nishamura and collaborators were able to unravel the FSHD mystery.

FSHD has no treatment or cure. “Our new data on mitochondrial protein dynamics in FSHD is particularly exciting because highlighting dysfunctions in protein turnover offers a potential new therapeutic route,” Nishimura said.

Next, researchers must find a way to increase protein recycling in the mitochondria and test if the improved turnover relieves FSHD symptoms. To do so, they need to develop better mouse models of FSHD. If the evidence continues to mount, therapeutic strategies such as might be used to restore order to the mitochondria in FSHD patients.